Compare Novavax Inc (NVAX) vs Ulta Beauty Inc (ULTA) Price & Performance

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Ulta Beauty (ULTA) trades at $537.69, down 2.0% today, with a bullish technical outlook from moving averages and a consensus analyst price target of $618.29. Recent earnings show mixed quarterly beats, with Q1 2026 EPS of $7.74 exceeding expectations, while revenue growth remains steady at $11.3B for 2025. The company maintains strong profitability with a net margin of 9.36% and ROE of 47.45%, supported by an omnichannel strategy highlighted in recent news.

The stock presents a buy opportunity with Wall Street optimism (56.53% buy ratings) and solid fundamentals, but risks include margin compression from rising costs and competitive pressures. Near-term catalysts include the Q2 2026 earnings report, with expected EPS of $6.17, and the transition from the Target partnership, viewed as a growth opportunity by analysts.